Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5).
Wilda
Monika
M
Perez
Antje Vega
AV
Bruch
Jochen
J
Woessmann
Wilhelm
W
Metzler
Markus
M
Fuchs
Uta
U
Borkhardt
Arndt
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D004268:DNA-Binding Proteins / Q000235:genetics*; D005047:Etoposide / Q000008:administration & dosage; D020690:GTPase-Activating Proteins / Q000235:genetics*; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D017404:In Situ Hybridization, Fluorescence; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage; D051788:Myeloid-Lymphoid Leukemia Protein; D018365:Neoplasm, Residual; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D011519:Proto-Oncogenes / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics*; D014157:Transcription Factors / Q000235:genetics*
C115971:ARHGAP26 protein, human; D004268:DNA-Binding Proteins; D020690:GTPase-Activating Proteins; C497422:KMT2A protein, human; D015514:Oncogene Proteins, Fusion; D012333:RNA, Messenger; D014157:Transcription Factors; D003561:Cytarabine; D051788:Myeloid-Lymphoid Leukemia Protein; D005047:Etoposide; D008942:Mitoxantrone; D011495:Histone-Lysine N-Methyltransferase; D015255:Idarubicin